These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25071119)

  • 1. Reply to J. Richter et al.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Sep; 32(25):2823-5. PubMed ID: 25071119
    [No Abstract]   [Full Text] [Related]  

  • 2. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
    Richter J; Söderlund S; Lübking A; Dreimane A; Lotfi K; Markevärn B; Själander A; Saussele S; Olsson-Strömberg U; Stenke L
    J Clin Oncol; 2014 Sep; 32(25):2821-3. PubMed ID: 25071107
    [No Abstract]   [Full Text] [Related]  

  • 3. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
    Valent P
    Lancet Oncol; 2010 Nov; 11(11):1010-1. PubMed ID: 20965784
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to H. Kantarjian et al.
    Hehlmann R; Hasford J; Pfirrmann M; Lauseker M; Saußele S; Hochhaus A; ;
    J Clin Oncol; 2014 Sep; 32(27):3078-9. PubMed ID: 25002729
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
    Marin D
    J Clin Oncol; 2014 Feb; 32(5):379-84. PubMed ID: 24419129
    [No Abstract]   [Full Text] [Related]  

  • 6. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
    Hussein K; Bock O; Seegers A; Flasshove M; Henneke F; Buesche G; Kreipe HH
    Blood; 2007 May; 109(9):4106-7. PubMed ID: 17449802
    [No Abstract]   [Full Text] [Related]  

  • 8. [Trends in molecular targeting therapeutics for chronic myeloid leukemia].
    Nagai T
    Rinsho Ketsueki; 2007 Oct; 48(10):1360-9. PubMed ID: 17933121
    [No Abstract]   [Full Text] [Related]  

  • 9. What does a deep molecular response signify?
    Politi J; Shah NP
    J Clin Oncol; 2014 Feb; 32(5):471-4. PubMed ID: 24297955
    [No Abstract]   [Full Text] [Related]  

  • 10. VEGF in chronic myeloid leukemia treated with interferon and imatinib.
    Aguayo A
    Leuk Res; 2014 Jun; 38(6):660-1. PubMed ID: 24726782
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic myeloid leukemia: where do we go now?
    Cortés JE
    Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S374-5. PubMed ID: 20007105
    [No Abstract]   [Full Text] [Related]  

  • 12. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.
    Kantarjian H; Cortes JE
    J Clin Oncol; 2014 Sep; 32(27):3077. PubMed ID: 25002733
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of chronic myeloid leukemia in chronic phase].
    Matsumura I
    Rinsho Ketsueki; 2014 Oct; 55(10):1853-9. PubMed ID: 25297749
    [No Abstract]   [Full Text] [Related]  

  • 14. Haematological cancer: Deep molecular response predicts survival in CML.
    Razzak M
    Nat Rev Clin Oncol; 2014 Feb; 11(2):68. PubMed ID: 24343665
    [No Abstract]   [Full Text] [Related]  

  • 15. The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib.
    Breccia M; Molica M; Colafigli G; Alimena G
    Acta Haematol; 2015; 134(1):57-8. PubMed ID: 25870940
    [No Abstract]   [Full Text] [Related]  

  • 16. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.
    Katagiri S; Umezu T; Ohyashiki JH; Ohyashiki K
    Br J Haematol; 2013 Jan; 160(2):269-71. PubMed ID: 23116058
    [No Abstract]   [Full Text] [Related]  

  • 17. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
    Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug.
    Smith KD; Paterson S
    Haematologica; 2005 Nov; 90 Suppl():ELT01. PubMed ID: 16266931
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
    J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Additional chromosomal abnormalities in dynamic of target therapy for chronic myeloid leukemia in children and adolescents].
    Andreeva SV; Drozdova VD
    Lik Sprava; 2014; (1-2):55-9. PubMed ID: 24908961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.